ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said that 27 evaluable patients for the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for indolent lymphoma were enrolled during October, according to a Monday filing with the Hong Kong bourse.
The cancer drug is known to simultaneously bind CD47 and CD20 expressed on malignant B cells, leading to improved therapeutic outcomes, the filing noted.
The company's shares were down over 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments